Mga Batayang Estadistika
| LEI | 549300AY704NEIRC4K64 |
| CIK | 1737953 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Replimune Group, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission |
|
| September 4, 2025 |
Replimune Announces Type A Meeting Scheduled with FDA Exhibit 99.1 Replimune Announces Type A Meeting Scheduled with FDA Woburn, MA, Sept. 2, 2025 – Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the complete response letter (CRL) for the Compa |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38596 REPL |
|
| August 7, 2025 |
Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update Exhibit 99.1 Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update Woburn, MA, August 7, 2025 – Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2025 and provided a business update. The Company |
|
| August 7, 2025 |
Amendment to Consulting Agreement This Amendment First to Consulting Agreement (the “1st Amendment”) is entered into as of May 30, 2025 (the “Amendment Effective Date”) by and between Replimune, Inc. |
|
| July 25, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| July 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitiv |
|
| July 22, 2025 |
Exhibit 99.1 Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma WOBURN, Mass., July 22, 2025 (GLOBE NEWSWIRE) - Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has |
|
| July 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2025 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 23, 2025 |
Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) Replimune Group, Inc. |
|
| May 23, 2025 |
Exhibit 4.8 REPLIMUNE GROUP, Inc. INDENTURE Dated as of [●] [●] Trustee TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS SECTION 1.01. Certain Terms Defined 1 SECTION 1.02. Other Definitions 5 SECTION 1.03. Rules of Construction 5 ARTICLE 2 SECURITY FORMS SECTION 2.01. Forms Generally 5 SECTION 2.02. Guarantees by Guarantor; Form of Guarantee; Release of Guarantee 5 SECTION 2.03. Form of T |
|
| May 23, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Replimune Group, Inc. |
|
| May 23, 2025 |
As filed with the Securities and Exchange Commission on May 22, 2025 As filed with the Securities and Exchange Commission on May 22, 2025 Registration No. |
|
| May 23, 2025 |
Exhibit 1.4 AMENDMENT NO. 2 TO THE SALES AGREEMENT LEERINK PARTNERS LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: This Amendment No. 2 to the Sales Agreement (this “Amendment”) is entered into as of November 25, 2024 by Replimune Group, Inc., a Delaware corporation (the “Company”), and Leerink Partners LLC, as sales agent (the “Agent”). The Company and |
|
| May 23, 2025 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Replimune Group, Inc. |
|
| May 23, 2025 |
As filed with the Securities and Exchange Commission on May 22, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 22, 2025 Registration Statement No. |
|
| May 23, 2025 |
As filed with the Securities and Exchange Commission on May 22, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 22, 2025 Registration Statement No. |
|
| May 23, 2025 |
Exhibit 1.5 AMENDMENT NO. 3 TO THE SALES AGREEMENT LEERINK PARTNERS LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 Ladies and Gentlemen: This Amendment No. 3 to the Sales Agreement (this “Amendment”) is entered into as of May 22, 2025 (the “Effective Date”) by Replimune Group, Inc., a Delaware corporation (the “Company”), and Leerink Partners LLC, as sales agent (the “Agent”). |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission File |
|
| May 22, 2025 |
REPLIMUNE GROUP, INC. AMENDED AND RESTATED INSIDER TRADING POLICY I. Introduction The purpose of this insider trading policy (the “Policy”) is to reduce the risk that any employee, executive officer or member of the Board of Directors (the “Board”) of Replimune Group, Inc. or any of its subsidiaries or certain family members might be found to have engaged in insider trading in violation of securit |
|
| May 22, 2025 |
REPLIMUNE GROUP, INC. CLAWBACK POLICY Article I. PURPOSE AND GENERAL TERMS Section 1.Purpose. (a)Replimune Group, Inc. (the “Company”) has adopted this Compensation Recoupment Policy (this “Policy”) to implement a mandatory clawback policy in the event of a Restatement in compliance with the applicable rules of the Nasdaq Stock Market (“Nasdaq”), which is set forth in Article 2 of this Policy. (b) |
|
| May 22, 2025 |
DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of Replimune Group, Inc. |
|
| May 22, 2025 |
Exhibit 99.1 Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update · BLA priority review of RP1 plus nivolumab in advanced melanoma proceeding on schedule; manufacturing inspections and late cycle review meeting complete · Full commercial infrastructure for launch in place ahead of July 22nd PDUFA date · Conference call today at 8:00 AM ET Woburn |
|
| May 22, 2025 |
Subsidiaries of the Registrant. EXHIBIT 21.1 Subsidiaries of Replimune Group, Inc. Name of Subsidiary Jurisdiction Replimune, Inc. Delaware Replimune Limited United Kingdom Replimune Securities Corporation Massachusetts Replimune (Ireland) Limited Ireland EU1/ 55029326.1 |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38596 R |
|
| April 25, 2025 |
As filed with the Securities and Exchange Commission on April 25, 2025 As filed with the Securities and Exchange Commission on April 25, 2025 Registration No. |
|
| April 25, 2025 |
Replimune Group, Inc. 2025 Inducement Grant Incentive Compensation Plan. Exhibit 99.3 REPLIMUNE GROUP, INC. 2025 INDUCEMENT GRANT INCENTIVE COMPENSATION PLAN Effective as of April 24, 2025 (the “Effective Date”), the Replimune Group, Inc. 2025 Inducement Grant Incentive Compensation Plan, as in effect from time to time (the “Plan”) is hereby established. The Plan is intended to assist the Company and its subsidiaries in attracting and retaining Employees (as defined be |
|
| April 25, 2025 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Replimune Group, Inc. |
|
| March 14, 2025 |
As filed with the Securities and Exchange Commission on March 14, 2025 As filed with the Securities and Exchange Commission on March 14, 2025 Registration No. |
|
| March 14, 2025 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Replimune Group, Inc. |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2025 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 7, 2025 |
Exhibit 10.1 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made as of March 5, 2025 by and among Replimune Group, Inc., a Delaware corporation (the “Company”), and the Persons listed on the attached Schedule A who are signatories to this Agreement (each an “Investor”, and collectively, the “Investors”). Unless otherwise defined herein, capitalized terms use |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2025 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission |
|
| February 12, 2025 |
Exhibit 99.1 Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update · U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for priority review with a PDUFA date of July 22, 2025 · IGNYTE-3 confirmatory trial of RP1(vusolimogene oderparepvec) plus nivolumab in advanc |
|
| February 12, 2025 |
As filed with the Securities and Exchange Commission on February 12, 2025 As filed with the Securities and Exchange Commission on February 12, 2025 Registration No. |
|
| February 12, 2025 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Replimune Group, Inc. |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38596 |
|
| February 10, 2025 |
February 10, 2025 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| January 22, 2025 |
PDUFA action date of July 22, 2025, with priority review Exhibit 99.1 Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma January 21, 2025 PDUFA action date of July 22, 2025, with priority review WOBURN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) - Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapie |
|
| January 22, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission |
|
| January 17, 2025 |
As filed with the Securities and Exchange Commission on January 17, 2025 As filed with the Securities and Exchange Commission on January 17, 2025 Registration No. |
|
| January 17, 2025 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Replimune Group, Inc. |
|
| December 20, 2024 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Replimune Group, Inc. |
|
| December 20, 2024 |
As filed with the Securities and Exchange Commission on December 20, 2024 As filed with the Securities and Exchange Commission on December 20, 2024 Registration No. |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2024 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commissi |
|
| December 4, 2024 |
Exhibit 4.1 REPLIMUNE GROUP, INC. FORM OF WARRANT TO PURCHASE COMMON STOCK Number of Shares: [●] (subject to adjustment) Warrant No. [●] Original Issue Date: [●], 2024 Replimune Group, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [●] or its registered assigns (the “Holder”), i |
|
| November 27, 2024 |
Replimune Announces Pricing of Upsized Public Offering Exhibit 99.2 Replimune Announces Pricing of Upsized Public Offering November 25, 2024 BOSTON, November 25, 2024 (GLOBE NEWSWIRE) - Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the pricing of its public offering of 6,923,000 shares of its common stock at a public offering price of $13.00 p |
|
| November 27, 2024 |
Underwriting Agreement dated November 25, 2024 Exhibit 1.1 ExECUTION VERSION Replimune Group, Inc. 6,923,000 Shares of Common Stock Pre-Funded Warrants to Purchase 3,846,184 Shares of Common Stock Underwriting Agreement November 25, 2024 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 Ladies and Gentlemen: Replimune Group, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to Leerink P |
|
| November 27, 2024 |
Exhibit 4.1 REPLIMUNE GROUP, INC. FORM OF WARRANT TO PURCHASE COMMON STOCK Number of Shares: [●] (subject to adjustment) Warrant No. [●] Original Issue Date: [●], 2024 Replimune Group, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [●] or its registered assigns (the “Holder”), i |
|
| November 27, 2024 |
Replimune Announces Proposed Public Offering Exhibit 99.1 Replimune Announces Proposed Public Offering WOBURN, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) - Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced a proposed public offering of $125 million of shares of its common stock and pre-funded warrants to purchase shares of common stock. All s |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2024 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission |
|
| November 26, 2024 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-273633 Prospectus supplement (To prospectus dated July 22, 2024) Replimune Group, Inc. 6,923,000 shares of common stock Pre-funded warrants to purchase 3,846,184 shares of common stock We are offering 6,923,000 shares of our common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,846 |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2024 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission |
|
| November 25, 2024 |
Subject to completion, dated November 25, 2024 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| November 21, 2024 |
Exhibit 99.1 Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway WOBURN, Mass., November 21, 2024 – Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it has submitted a biologics licens |
|
| November 21, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2024 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission |
|
| November 19, 2024 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Replimune Group, Inc. |
|
| November 19, 2024 |
As filed with the Securities and Exchange Commission on November 19, 2024 As filed with the Securities and Exchange Commission on November 19, 2024 Registration No. |
|
| November 14, 2024 |
SC 13G/A 1 d910286dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Replimune Group, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 76029N106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| November 14, 2024 |
REPL / Replimune Group, Inc. / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SC 13G/A 1 tm2426483d10sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 2)* Replimune Group, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 76029N106 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the approp |
|
| November 14, 2024 |
REPL / Replimune Group, Inc. / Omega Fund IV, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d815643dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 5)* Replimune Group, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 76029N106 (CUSIP Number) Septembe |
|
| November 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission |
|
| November 12, 2024 |
Form of U.K. Inducement Restricted Stock Unit Grant Agreement. U.K. Form RSU Inducement Grant (Sept 2024) REPLIMUNE GROUP, INC. RESTRICTED STOCK UNIT GRANT AGREEMENT Participant: %%FIRSTNAME%-% %%LASTNAME%-% Date of Grant: %%OPTIONDATE,'Month DD, YYYY'%-% Restricted Units Granted: %%TOTALSHARESGRANTED,'999,999,999'%-% RECITALS Pursuant to the terms of the employment engagement between Replimune Limited, (the “Company”) and the Participant (as it may be amende |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38596 |
|
| November 12, 2024 |
Executive Severance Plan for Chief-Level Executives REPLIMUNE, INC. EXECUTIVE SEVERANCE PLAN FOR CHIEF-LEVEL EXECUTIVES Replimune, Inc. has adopted this Executive Severance Plan for Chief-Level Executives for the benefit of chief-level executives of the Company and its Subsidiaries in the United States, on the terms and conditions hereinafter stated. All capitalized terms used herein are defined in the text or in Section 1 hereof. The Plan, as set |
|
| November 12, 2024 |
Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update Exhibit 99.1 Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update • Completed Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) and remain on track to submit a BLA for RP1 plus nivolumab in anti-PD1 failed melanoma via the accelerated approval pathway before the end of the year • IGNYTE-3 confirmatory trial of R |
|
| November 12, 2024 |
Form of U.K. Inducement Stock Option Grant Agreement U.K. Form NQSO Inducement Grant (Sept 2024) REPLIMUNE GROUP, INC. NONQUALIFIED STOCK OPTION GRANT AGREEMENT Participant: %%FIRSTNAME%-% %%LASTNAME%-% Date of Grant: %%OPTIONDATE,'Month DD, YYYY'%-% Shares subject to the Option: %%TOTALSHARESGRANTED,'999,999,999'%-% Option Price: %%OPTIONPRICE,'$999,999,999.99'%-% RECITALS Pursuant to the terms of the employment engagement between Replimune, Inc. ( |
|
| October 16, 2024 |
As filed with the Securities and Exchange Commission on October 16, 2024 As filed with the Securities and Exchange Commission on October 16, 2024 Registration No. |
|
| October 16, 2024 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Replimune Group, Inc. |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2024 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission |
|
| August 13, 2024 |
Replimune Group, Inc. 500 Unicorn Park Drive, Suite 303 Woburn, MA 01801 Replimune Group, Inc. 500 Unicorn Park Drive, Suite 303 Woburn, MA 01801 August 13, 2024 VIA EDGAR SUBMISSION AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Daniel Crawford Re: Replimune Group, Inc. Registration Statement on Form S-3 Filed August 8, 2024 (Registration No. |
|
| August 8, 2024 |
Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) Replimune Group, Inc. |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38596 REPL |
|
| August 8, 2024 |
As filed with the Securities and Exchange Commission on August 8, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 8, 2024 Registration Statement No. |
|
| August 8, 2024 |
Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update Exhibit 99.1 Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update · Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) scheduled for September and BLA submission planned for 2H 2024 · Enrollment of first patient in Phase 3 confirmatory trial of RP1 in advanced melanoma expected in Q3 2024 · Protocol finalized for |
|
| July 19, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive |
|
| June 13, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of June 12, 2024 by and among Replimune Group, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and delivering this |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 13, 2024 |
Form of Registration Rights Agreement Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [●], is entered into by and among Replimune Group, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively, together with their respective permitted assigns, the “Investors”). Capitalized terms used herein and |
|
| June 13, 2024 |
Exhibit 99.1 Replimune Announces $100 Million Private Placement Financing - Led by a life-sciences focused institutional investor, with participation from Redmile Group, RTW Investments, Boxer Capital and other institutional investors- - Financing follows strong primary analysis data from the RP1 IGNYTE clinical trial in anti-PD1 failed melanoma; BLA filing expected in 2H 2024 - - Proceeds enable |
|
| June 13, 2024 |
Exhibit 4.1 REPLIMUNE GROUP, INC. FORM OF WARRANT TO PURCHASE COMMON STOCK Number of Shares: [·] (subject to adjustment) Warrant No. [·] Original Issue Date: June [·]. 2024 Replimune Group, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [·] or its registered assigns (the “Holder |
|
| June 6, 2024 |
Exhibit 99.1 Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma Primary endpoint data shows 12-month overall response rate (ORR) of 33.6% Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3 confirmatory trial in Q3 202 |
|
| June 6, 2024 |
Exhibit 99.2 IGNYTE Investor Event (6/6/24) 1 Primary Analysis of the IGNYTE Registrational Cohort in Anti-PD1 Failed Melanoma June 6, 2024 IGNYTE Investor Event (6/6/24) 2 Safe Harbor Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission File |
|
| June 3, 2024 |
Exhibit 99.1 Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - Investigator-assessed 12-month results from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD-1 failed melanoma demonstrate an overall response rate of 32.7% and duration of response consistent with the previously reported 6-month data |
|
| June 3, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission File |
|
| May 16, 2024 |
Subsidiaries of the Registrant. EXHIBIT 21.1 Subsidiaries of Replimune Group, Inc. Name of Subsidiary Jurisdiction Replimune, Inc. Delaware Replimune Limited United Kingdom Replimune Securities Corporation Massachusetts Replimune (Ireland) Limited Ireland EU1/ 55029326.1 |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38596 R |
|
| May 16, 2024 |
As filed with the Securities and Exchange Commission on May 16, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 16, 2024 Registration Statement No. |
|
| May 16, 2024 |
EXECUTION VERSION SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Replimune, Inc. |
|
| May 16, 2024 |
Replimune Inc 500 Unicorn Park Dr. Woburn, MA 01801 PERSONAL & CONFIDENTIAL March 26 , 2024 Pamela Esposito RE: Separation Agreement and Release Dear Pamela: This letter of agreement and general release (“Agreement”) confirms our mutual agreement regarding the terms and conditions of your separation from employment with Replimune, Inc. (the “Company”) without Cause (as defined in the Employment Ag |
|
| May 16, 2024 |
As filed with the Securities and Exchange Commission on May 16, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 16, 2024 Registration Statement No. |
|
| May 16, 2024 |
Replimune Inc 500 Unicorn Park Dr. Woburn, MA 01801 PERSONAL & CONFIDENTIAL March 31, 2024 Tanya Lewis RE: Separation Agreement and Release Dear Tanya: This letter of agreement and general release (“Agreement”) confirms our mutual agreement regarding the terms and conditions of your separation from employment with Replimune, Inc. (the “Company”) without Cause (as defined in the Employment Agreemen |
|
| May 16, 2024 |
Replimune Group, Inc. Clawback Policy REPLIMUNE GROUP, INC. CLAWBACK POLICY Article I. PURPOSE AND GENERAL TERMS Section 1.Purpose. (a)Replimune Group, Inc. (the “Company”) has adopted this Compensation Recoupment Policy (this “Policy”) to implement a mandatory clawback policy in the event of a Restatement in compliance with the applicable rules of the Nasdaq Stock Market (“Nasdaq”), which is set forth in Article 2 of this Policy. (b) |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2024 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission File |
|
| May 16, 2024 |
EXECUTION VERSION SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Replimune, Inc. |
|
| May 16, 2024 |
Exhibit 99.1 Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update · Twelve-month primary analysis results by independent central review from the IGNYTE clinical trial of RP1 (vusolimogene oderparepvec) in anti-PD1 failed melanoma expected Q2 2024 · Recent Type C CMC meeting with the U.S. Food and Drug Administration (FDA) supports IGNYTE Biolo |
|
| May 16, 2024 |
April 2024 U.K. PSU Form REPLIMUNE GROUP, INC. 2018 OMNIBUS INCENTIVE COMPENSATION PLAN PERFORMANCE STOCK UNIT SUMMARY OF GRANT Replimune Group, Inc., a Delaware corporation (the “Company” or “Employer”), pursuant to its 2018 Omnibus Incentive Compensation Plan and the Sub-Plan for U.K. Employees thereunder (together, the “Plan”), hereby grants to the individual listed below (the “Participant”), t |
|
| May 16, 2024 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Replimune Group, Inc. |
|
| May 16, 2024 |
Consulting Agreement, dated as of March 25, 2024, by and between Robert Coffin and Replimune, Inc. CONSULTING AGREEMENT This CONSULTING AGREEMENT (this “Agreement”) is dated as of March 25, 2024, by and between Replimune, Inc. |
|
| May 16, 2024 |
Form of Performance Stock Unit Award Agreement under 2018 Omnibus Incentive Compensation Plan April 2024 U.S. PSU Form REPLIMUNE GROUP, INC. 2018 OMNIBUS INCENTIVE COMPENSATION PLAN PERFORMANCE STOCK UNIT SUMMARY OF GRANT Replimune Group, Inc., a Delaware corporation (the “Company” or “Employer”), pursuant to its 2018 Omnibus Incentive Compensation Plan (the “Plan”), hereby grants to the individual listed below (the “Participant”), this performance stock unit award representing the target |
|
| May 16, 2024 |
Consulting Agreement, dated as of March 31, 2024, by and between Tanya Lewis and Replimune, Inc. CONSULTING AGREEMENT This CONSULTING AGREEMENT (this “Agreement”) is dated as of March 31, 2024, by and between Replimune, Inc. |
|
| May 16, 2024 |
Consulting Agreement, dated as of March 26, 2024, by and between Pamela Esposito and Replimune, Inc. CONSULTING AGREEMENT This CONSULTING AGREEMENT (this “Agreement”) is dated as of March 26, 2024 by and between Replimune, Inc. |
|
| May 16, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Replimune Group, Inc. |
|
| May 16, 2024 |
DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of Replimune Group, Inc. |
|
| May 16, 2024 |
As filed with the Securities and Exchange Commission on May 16, 2024 As filed with the Securities and Exchange Commission on May 16, 2024 Registration No. |
|
| May 16, 2024 |
Exhibit 1.3 AMENDMENT NO. 1 TO THE SALES AGREEMENT LEERINK PARTNERS LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: This Amendment No. 1 to the Sales Agreement (this “Amendment”) is entered into as of May 16, 2024 by Replimune Group, Inc., a Delaware corporation (the “Company”), and Leerink Partners LLC, as sales agent (the “Agent”), which are the parties |
|
| May 16, 2024 |
Replimune Inc 500 Unicorn Park Dr. Woburn, MA 01801 PERSONAL & CONFIDENTIAL March 25, 2024 Robert Coffin RE: Separation and Transition Agreement Dear Rob: This letter of agreement and general release (“Agreement”) confirms our agreement regarding your transition from employment with Replimune, Inc. (the “Company”) by mutual agreement, which is being treated as a termination by the Company without |
|
| May 16, 2024 |
Form of Inducement Stock Option Grant Agreement. U.S. Form NQSO Inducement Grant (April 2024) REPLIMUNE GROUP, INC. NONQUALIFIED STOCK OPTION GRANT AGREEMENT Participant: %%FIRSTNAME%-% %%LASTNAME%-% Date of Grant: %%OPTIONDATE,'Month DD, YYYY'%-% Shares subject to the Option: %%TOTALSHARESGRANTED,'999,999,999'%-% Option Price: %%OPTIONPRICE,'$999,999,999.99'%-% RECITALS Pursuant to the terms of the employment engagement between Replimune, Inc. |
|
| May 16, 2024 |
Form of Inducement Restricted Stock Unit Grant Agreement. U.S. Form RSU Inducement Grant (April 2024) REPLIMUNE GROUP, INC. RESTRICTED STOCK UNIT GRANT AGREEMENT Participant: %%FIRSTNAME%-% %%LASTNAME%-% Date of Grant: %%OPTIONDATE,'Month DD, YYYY'%-% Restricted Units Granted: %%TOTALSHARESGRANTED,'999,999,999'%-% RECITALS Pursuant to the terms of the employment engagement between Replimune, Inc. (the “Company”) and the Participant (as it may be amended |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 26, 2024 |
Exhibit 99.1 Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the company for commercialization Preparations on track to submit RP1 biologics license application (BLA) in 2H 2024 Woburn, Mass., March 26, 2024 – Replimune Group, Inc. (NASDA |
|
| February 14, 2024 |
REPL / Replimune Group, Inc. / Omega Fund IV, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d782161dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 4)* Replimune Group, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 76029N106 (CUSIP Number) December |
|
| February 14, 2024 |
REPL / Replimune Group, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm245846d15sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7) Replimune Group, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 76029N106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Che |
|
| February 14, 2024 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Replimune Group, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 76029N106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 14, 2024 |
EX-99.1 2 tm245846d15ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 p |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2024 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38596 |
|
| February 8, 2024 |
Execution Version SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This second Amendment to Loan and Security Agreement (this “Amendment”) is dated as of December 22, 2023 and is entered into by and among Replimune Group, Inc. |
|
| February 8, 2024 |
Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update • Positive data update in December 2023 for all 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma demonstrating durability of response • Centrally reviewed 12-month primary analysis data from IGNYTE trial of RP1 in anti-PD1 failed melanoma and biologics license |
|
| January 10, 2024 |
REPL / Replimune Group, Inc. / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 8, 2024 |
Exhibit 99.1 Safe harbor Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the advancement, timing and sufficiency of our clinical trials, patient enro |
|
| January 8, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission F |
|
| December 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2023 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission |
|
| December 5, 2023 |
Exhibit 99.1 Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cem |
|
| December 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2023 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission |
|
| November 7, 2023 |
U.S. Form Inducement Grant REPLIMUNE GROUP, INC. RESTRICTED STOCK UNIT GRANT AGREEMENT Participant: Emily Hill Date of Grant: September 18, 2023 Restricted Units Granted: 83,330 RECITALS Pursuant to the terms of the Employment Agreement dated August 31, 2023 between Replimune, Inc. (the “Company”) and the Participant (as it may be amended from time to time, the “Employment Agreement”), the Company |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38596 |
|
| November 7, 2023 |
Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update The Company plans to hold a conference call in early December to provide a comprehensive RP1 skin cancer program update including: · Topline data from the CERPASS clinical trial of RP1 combined with Libtayo in cutaneous squamous cell carcinoma · An initial data snapshot for all 140 patients in |
|
| November 7, 2023 |
Agreement, dated as of August 31, 2023, by and between Emily Hill and Replim EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Replimune, Inc. |
|
| November 7, 2023 |
Stock Option Grant Agreement, effective as of U.S. Form Inducement Grant REPLIMUNE GROUP, INC. NONQUALIFIED STOCK OPTION GRANT AGREEMENT Participant: Emily Hill Date of Grant: September 18, 2023 Shares subject to the Option: 125,000 per-Share Exercise Price: $18.00 RECITALS Pursuant to the terms of the Employment Agreement dated August 31, 2023 between Replimune, Inc. (the “Company”) and the Participant (as it may be amended from time to time |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission |
|
| November 7, 2023 |
Employment Agreement, dated as of AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is entered into by and among Replimune, Inc. |
|
| September 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2023 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commissio |
|
| September 19, 2023 |
Replimune Announces Appointment of Emily Hill as Chief Financial Officer Exhibit 99.1 Replimune Announces Appointment of Emily Hill as Chief Financial Officer Woburn, MA, September 19, 2023 – Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the appointment of Emily Hill as Chief Financial Officer. Ms. Hill was most recently CFO of the commercial sta |
|
| September 7, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission |
|
| August 3, 2023 |
Exhibit 4.7 REPLIMUNE GROUP, Inc. INDENTURE Dated as of [●] [●] Trustee TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS SECTION 1.01. Certain Terms Defined 1 SECTION 1.02. Other Definitions 5 SECTION 1.03. Rules of Construction 5 ARTICLE 2 SECURITY FORMS SECTION 2.01. Forms Generally 5 SECTION 2.02. Guarantees by Guarantor; Form of Guarantee; Release of Guarantee 5 SECTION 2.03. Form of Trustee’s Cer |
|
| August 3, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Replimune Group, Inc. |
|
| August 3, 2023 |
Exhibit 99.2 FOR IMMEDIATE RELEASE Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB099280 in Patients with Cutaneous Squamous Cell Carcinoma Initial study in the neoadjuvant setting designed to assess RP1 in combination with the small molecule, oral PD-L1 inhibitor, INCB99280 WOBURN, Mass. and WILMINGTON, Del., July 31, 2023 – Replimune Gro |
|
| August 3, 2023 |
Exhibit 1.2 REPLIMUNE GROUP, INC. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENT August 3, 2023 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Replimune Group, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: 1. Iss |
|
| August 3, 2023 |
As filed with the Securities and Exchange Commission on August 3, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 3, 2023 Registration Statement No. |
|
| August 3, 2023 |
Inc., Replimune Limited and Hercules Capital, Execution Version FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This First Amendment to Loan and Security Agreement (this “Amendment”) is dated as of June 28, 2023 and is entered into by and among Replimune Group, Inc. |
|
| August 3, 2023 |
Replimune Inc 500 Unicorn Park Dr. Woburn, MA 01801 PERSONAL & CONFIDENTIAL May 18, 2023 Jean Franchi 205 Pleasant Street Norwell, MA 02061 RE: Separation Agreement and Release Dear Jean: This letter of agreement and general release (“Agreement”) confirms our mutual agreement regarding the terms and conditions of your separation from employment with Replimune, Inc. (the “Company”) without Cause (a |
|
| August 3, 2023 |
EXHIBIT B REPLIMUNE, INC. CONSULTING AGREEMENT This CONSULTING AGREEMENT (this “Agreement”) is dated as of May 18, 2023, by and between Replimune, Inc. (the “Company”) and Jean Franchi (the “Consultant,” together with the Company, the “Parties” and each, a “Party”). This Agreement will be effective on June 3, 2023. For the avoidance of doubt, if the Consultant does not execute or revokes the Separ |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38596 REPL |
|
| August 3, 2023 |
Exhibit 99.1 Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update Topline data from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo® (cemiplimab-rwlc) in cutaneous squamous cell carcinoma expected in early Q4 2023 and Biologics License Application submission anticipated in Q1/2 2024 Cost sharing collaboration in cutaneous squamou |
|
| July 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitiv |
|
| July 26, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| July 20, 2023 |
Replimune Announces Sander Slootweg will Depart from its Board of Directors Exhibit 99.1 Replimune Announces Sander Slootweg will Depart from its Board of Directors WOBURN, Mass., July 20, 2023 – Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced Sander Slootweg, founder and managing partner at Forbion, will not seek to be reappointed as a non |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2023 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 5, 2023 |
Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors Exhibit 99.1 Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors Woburn, MA, June 5, 2023 – Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced the appointment of Veleka R. Peeples-Dyer to the Company’s Board of Directors effective June 1, 2023. “We |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission File |
|
| May 18, 2023 |
DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of Replimune Group, Inc. |
|
| May 18, 2023 |
As filed with the Securities and Exchange Commission on May 18, 2023 As filed with the Securities and Exchange Commission on May 18, 2023 Registration No. |
|
| May 18, 2023 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Replimune Group, Inc. |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38596 R |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission File |
|
| May 18, 2023 |
U.S. Form Inducement Grant REPLIMUNE GROUP, INC. NONQUALIFIED STOCK OPTION GRANT AGREEMENT Participant: Christopher Sarchi Date of Grant: December 30, 2022 Shares subject to the Option: 82,500 per-Share Exercise Price: $27.20 RECITALS Pursuant to the terms of the Employment Agreement dated December 30, 2022 between Replimune, Inc. (the “Company”) and the Participant (as it may be amended from time |
|
| May 18, 2023 |
Subsidiaries of the Registrant. EXHIBIT 21.1 Subsidiaries of Replimune Group, Inc. Name of Subsidiary Jurisdiction Replimune, Inc. Delaware Replimune Limited United Kingdom Replimune Securities Corporation Massachusetts Replimune (Ireland) Limited Ireland EU1/ 55029326.1 |
|
| May 18, 2023 |
Exhibit 99.1 Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update Topline data disclosure from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo® (cemiplimab-rwlc) in cutaneous squamous cell carcinoma (CSCC) on track for Q3 2023 and Biologics License Application (BLA) submission on track for Q1 2024 Completed enroll |
|
| May 18, 2023 |
DATED 23 MARCH 2023 (1) MEPC MILTON PARK NO. 1 LIMITED AND MEPC MILTON PARK NO. 2 LIMITED and (2) REPLIMUNE LIMITED LEASE relating to 68GH Innovation Drive MILTON PARK PRESCRIBED CLAUSES LR1. Date of lease : 23 March 2023 LR2. Title number(s) LR2.1 Landlord’s title number(s) ON130606 LR2.2 Other title number(s) BK102078, ON122118, ON122717, ON145942, ON146219, ON225380, ON38283, ON72772, ON96949, |
|
| May 18, 2023 |
U.S. Form Inducement Grant REPLIMUNE GROUP, INC. RESTRICTED STOCK UNIT GRANT AGREEMENT Participant: Christopher Sarchi Date of Grant: December 30, 2022 Restricted Units Granted: 55,000 RECITALS Pursuant to the terms of the Employment Agreement dated December 30, 2022 between Replimune, Inc. (the “Company”) and the Participant (as it may be amended from time to time, the “Employment Agreement”), th |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission |
|
| February 14, 2023 |
REPL / Replimune Group Inc / Redmile Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm236041d11sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6) Replimune Group, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 76029N106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| February 14, 2023 |
EX-99.1 2 tm236041d11ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 p |
|
| February 14, 2023 |
REPL / Replimune Group Inc / BAKER BROS. ADVISORS LP - SC 13G Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Replimune Group, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. February 14, 2023 BAKER BROS. ADVISORS LP By: Baker Bros. Advisors (GP) LLC, its |
|
| February 13, 2023 |
REPL / Replimune Group Inc / Omega Fund IV, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d442637dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 3)* Replimune Group, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 76029N106 (CUSIP Number) December |
|
| February 9, 2023 |
Exhibit 99.1 Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update Strengthened balance sheet raising gross $259 million through an upsized public offering in December, extending cash runway into H2 2025 and increasing operational and strategic flexibility Topline data from the CERPASS registration-directed clinical trial evaluating RP1 in cutaneous squamous cell c |
|
| February 9, 2023 |
EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Replimune, Inc. |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38596 |
|
| February 9, 2023 |
EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Replimune, Inc. |
|
| February 9, 2023 |
AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Amendment”) is entered into by and between Replimune, Inc. |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2023 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission |
|
| January 4, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2023 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission F |
|
| January 4, 2023 |
Exhibit 99.1 Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer Woburn, MA, January 4, 2023 ? Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies (TDOIs), announced today the appointment of |
|
| December 12, 2022 |
Underwriting Agreement dated December 8, 2022 Exhibit 1.1 EXECUTION VERSION Replimune Group, Inc. 5,374,486 Shares of Common Stock Pre-Funded Warrants to Purchase 4,200,000 Shares of Common Stock Underwriting Agreement December 8, 2022 J.P. Morgan Securities LLC SVB Securities LLC Piper Sandler & Co. BMO Capital Markets Corp. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison |
|
| December 12, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission |
|
| December 12, 2022 |
Replimune Announces Proposed Public Offering Exhibit 99.1 Replimune Announces Proposed Public Offering Boston, MA ? December 7, 2022 ? Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced a proposed public offering of $125 million of shares of its common stock and pre-funded warrants to purchase shares of common st |
|
| December 12, 2022 |
Replimune Announces Pricing of Public Offering Exhibit 99.2 Replimune Announces Pricing of Public Offering Boston, MA ? December 8, 2022 ? Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced the pricing of its public offering of 5,374,486 shares of its common stock at a public offering price of $23.50 per share. In |
|
| December 12, 2022 |
424B5 1 tm2232159-2424b5.htm 424B5 TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-265805 Prospectus supplement (To prospectus dated July 27, 2022) Replimune Group, Inc. 5,374,486 shares of common stock Pre-funded warrants to purchase 4,200,000 shares of common stock We are offering 5,374,486 shares of our common stock and, in lieu of common stock to certain investors, pr |
|
| December 12, 2022 |
Form of Pre-Funded Warrant (2022) Exhibit 4.1 REPLIMUNE GROUP, INC. FORM OF WARRANT TO PURCHASE COMMON STOCK Number of Shares: [?] (subject to adjustment) Warrant No. [?] Original Issue Date: December [?], 2022 Replimune Group, Inc., a Delaware corporation (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [?] or its registered assigns (the ?Ho |
|
| December 7, 2022 |
Exhibit 99.2 Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update RP1 combined with nivolumab continues to demonstrate deep and durable responses in patients with anti-PD1 failed melanoma Overall response rate (ORR) of 36% and complete response (CR) rate of 20%, with clinically meaningful activity across a broad r |
|
| December 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission |
|
| December 7, 2022 |
424B5 1 tm2232159-1424b5.htm 424B5 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and they are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale thereof is not permitted. Filed pu |
|
| December 7, 2022 |
Exhibit 99.1 Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma RP3 will be developed in combination with atezolizumab and bevacizumab for the third-line treatment of colorectal cancer (CRC) and for the first- and second-line treatment of hepatocellular carcinoma (HCC) Includes cost sharing for development |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* REPLIMUNE GROUP, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 76029N106 (CUSIP Number) Atlas Venture Attention: Ommer Chohan, Chief Financial Officer 300 Technology Square, 8th Floor Cambridge, MA 02139 |
|
| November 18, 2022 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, $0.001 par value per share, of Replimune Group, Inc., |
|
| November 18, 2022 |
REPL / Replimune Group Inc / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5) Replimune Group, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 76029N106 (CUSIP Number) November 14, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| November 3, 2022 |
Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission |
|
| November 3, 2022 |
Exhibit 99.1 Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update Completed enrollment in the CERPASS registration-directed clinical trial evaluating RP1 in cutaneous squamous cell carcinoma (CSCC); primary analysis data expected to be released in H1 2023 Six-month follow-up data from the first 75 patients enrolled in the IGNYTE clinical trial cohort of RP1 combi |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38596 |
|
| October 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2022 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission F |
|
| October 7, 2022 |
Replimune Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. Exhibit 99.1 Replimune Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. Woburn, MA, October 7, 2022 ? Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that it has obtained a $200 million non-dilutive term loan facility from Hercules Cap |
|
| September 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* REPLIMUNE GROUP, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 76029N106 (CUSIP Number) Atlas Venture Attention: Ommer Chohan, Chief Financial Officer 300 Technology Square, 8th Floor Cambridge, MA 02139 |
|
| September 8, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2022 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission |
|
| August 4, 2022 |
Exhibit 99.1 Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update Target enrollment of 180 patients reached in the CERPASS randomized controlled registration-directed clinical trial evaluating RP1 in cutaneous squamous cell carcinoma (CSCC); primary analysis data expected to be released in H1 2023 First 75 patients enrolled in the IGNYTE clinical trial cohort of R |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38596 REPL |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment ???) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| July 27, 2022 |
Replimune Group, Inc. 500 Unicorn Park Drive Woburn, MA 01801 Replimune Group, Inc. 500 Unicorn Park Drive Woburn, MA 01801 July 27, 2022 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Daniel Crawford Re: Replimune Group, Inc. Registration Statement on Form S-3 Filed June 23, 2022 (Registration No. 333-265805) Dear |
|
| July 27, 2022 |
Definitive Proxy Statement on Schedule 14A filed with the SEC on July 27, 2022 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment ???) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule |
|
| June 23, 2022 |
As filed with the Securities and Exchange Commission on June 23, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 23, 2022 Registration Statement No. |
|
| June 23, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Replimune Group, Inc. |
|
| June 23, 2022 |
EX-1.2 2 tm2219189d2ex1-2.htm EXHIBIT 1.2 Exhibit 1.2 REPLIMUNE GROUP, INC. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENT June 23, 2022 SVB SECURITIES LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Replimune Group, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Securities LLC (the “A |
|
| June 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2022 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 23, 2022 |
Exhibit 4.6 REPLIMUNE GROUP, Inc. INDENTURE Dated as of [?] [?] Trustee TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS SECTION 1.01. Certain Terms Defined 1 SECTION 1.02. Other Definitions 5 SECTION 1.03. Rules of Construction 5 ARTICLE 2 SECURITY FORMS SECTION 2.01. Forms Generally 5 SECTION 2.02. Guarantees by Guarantor; Form of Guarantee; Release of Guarantee 5 SECTION 2.03. Form of Trustee?s Cer |
|
| June 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2022 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission File |
|
| June 3, 2022 |
Replimune Announces the Departure of Jason Rhodes from its Board of Directors Exhibit 99.1 Replimune Announces the Departure of Jason Rhodes from its Board of Directors Woburn, MA, June 3, 2022 ? Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced Jason Rhodes, partner at Atlas Venture, has resigned from the company?s Board of Directors. Mr. Rhod |
|
| May 19, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission File |
|
| May 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from???????? ??to Commission file number 001-38596 R |
|
| May 19, 2022 |
REPLIMUNE GROUP, INC. 2018 OMNIBUS INCENTIVE COMPENSATION PLAN Effective as of the Effective Date (as defined below), the Replimune Group, Inc. 2018 Omnibus Incentive Compensation Plan (the ?Plan?) is hereby established. The purpose of the Plan is to provide employees of Replimune Group, Inc. (the ?Company?) and its subsidiaries, certain consultants and advisors who perform services for the Compan |
|
| May 19, 2022 |
Exhibit 4.3 to our Annual Report on Form 10-K for the fiscal year ended March 31, 2022 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of Replimune Group, Inc. |
|
| May 19, 2022 |
Subsidiaries of the Registrant. EXHIBIT 21.1 Subsidiaries of Replimune Group, Inc. Name of Subsidiary Jurisdiction Replimune, Inc. Delaware Replimune Limited United Kingdom Replimune Securities Corporation Massachusetts Replimune (Ireland) Limited Ireland EU1/ 55029326.1 |
|
| May 19, 2022 |
Exhibit 99.1 Replimune Reports Fiscal Fourth Quarter and Year-Ended 2022 Financial Results and Provides Corporate Update Enrollment in the CERPASS clinical trial with RP1 in cutaneous squamous cell carcinoma (CSCC) expected to be completed in mid-year 2022; top line data expected Q1 2023 Directional data from the first 75 patents with 6 months follow up from the IGNYTE clinical trial with RP1 in a |
|
| May 19, 2022 |
Replimune Inc 500 Unicorn Park Dr. Woburn, MA 01801 PERSONAL & CONFIDENTIAL August 25, 2021 (revised September 30, 2021) Andrea Pirzkall 17927 Mollypop Lane Cornelius NC 28031 RE: Separation Agreement and Release Dear Andrea: This letter of agreement and general release (?Agreement?) confirms our mutual agreement regarding the terms and conditions of your separation from employment with Replimune, |
|
| March 30, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2022 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 30, 2022 |
Exhibit 99.1 Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies RP1 combined with Opdivo? (nivolumab) continues to demonstrate deep and durable responses in patients with melanoma and non-melanoma skin cancers (NMSC); new positive initial data in patients with anti-PD1 failed NMSC Initial data shows clinical a |
|
| February 14, 2022 |
REPL / Replimune Group Inc / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4) Replimune Group, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 76029N106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 14, 2022 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, $0.001 par value per share, of Replimune Group, Inc., |
|
| February 14, 2022 |
REPL / Replimune Group Inc / Omega Fund IV, L.P. - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Replimune Group, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 76029N106 (CUSIP Number) December 31, 2021 (Date of Event Which |
|
| February 3, 2022 |
Exhibit 99.1 Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update Data expected to be presented at an investor event in March 2022: Data updates from the completed RP1 IGNYTE cohorts in anti-PD1 na?ve non-melanoma skin cancer (NMSC) and anti-PD1 na?ve and failed melanoma Initial data from the ongoing study in anti-PD1 failed NMSC and from the ARTACUS trial, a Phas |
|
| February 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38596 |
|
| February 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2022 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission |
|
| February 3, 2022 | ||
| January 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2022 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission |
|
| January 31, 2022 |
Replimune Announces the Departure of Dr. Otello Stampacchia from its Board of Directors Exhibit 99.1 Replimune Announces the Departure of Dr. Otello Stampacchia from its Board of Directors Woburn, MA, January 31, 2022 ? Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced Otello Stampacchia, Ph.D., of Omega Funds, has resigned from the company?s Board of Dir |
|
| January 10, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission |
|
| January 10, 2022 |
Exhibit 99.1 Replimune Provides 2021 Year End Review and Overview of Expected 2022 Milestones CERPASS clinical trial with RP1 in CSCC on track to complete enrollment mid-year with the primary analysis trigger six months thereafter IGNYTE anti-PD1 failed melanoma, evaluating RP1 in combination with Opdivo? on track to release interim data in late 2022 Phase 2 development plan for RP2/3 to be presen |
|
| December 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2021 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission |
|
| December 2, 2021 |
Replimune Appoints Christy Oliger to its Board of Directors Exhibit 99.1 Replimune Appoints Christy Oliger to its Board of Directors Woburn, MA, December 2, 2021 ? Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing a range of product candidates derived from its oncolytic immuno-gene therapy platform, today announced the appointment of Christy Oliger to the Company?s Board of Directors effective December 1, 2021. ?We are delighted to w |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38596 |
|
| November 4, 2021 |
Execution Copy AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into by and between Replimune, Inc. |
|
| November 4, 2021 |
Exhibit 99.1 Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update RP1; Full patient accrual in CERPASS registration-directed clinical trial continues to be expected in mid-year 2022 with the primary data trigger expected in late 2022. Interim data in the IGNYTE anti-PD1 failed registration directed melanoma cohort continues to be expected in late 2022 RP2; Update |
|
| November 4, 2021 |
Execution Copy AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into by and between Replimune, Inc. |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission |
|
| September 9, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2021 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission |
|
| August 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2021 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission F |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38596 REPL |
|
| August 6, 2021 |
Exhibit 99.1 Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update Updated complete and durable response data in RP1 (vusolimogene oderparepvec) skin cancer cohorts support the ongoing registration directed development programs in CSCC and anti-PD-1 failed melanoma, with full accrual for both programs expected in mid-2022 Initial data with RP2 as monotherapy and in |
|
| August 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2021 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 001-38596 82-2082553 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 22, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment???????? ??) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by |
|
| July 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitiv |
